Table 5.
Thirty-day rate of postprocedure events among those who interrupted or did not interrupt therapy prior to the procedure
| Event | Interruption | No interruption | OR [interruption vs no interruption] (95% CI) | Interaction P† | Adjusted OR [interruption vs no interruption] (95% CI)‡ | Interaction P† |
|---|---|---|---|---|---|---|
| Events/procedures (%) [n]* | Events/procedures (%) [n]* | |||||
| Stroke/systemic embolism | ||||||
| Overall | 19/5741 (0.33) | 23/3413 (0.67) | 0.490 (0.267-0.901) | 0.354 (0.168-0.747) | ||
| Apixaban | 9/2877 (0.31) | 7/1747 (0.40) | 0.781 (0.290-2.103) | .2352 | 0.651 (0.215-1.970) | .3121 |
| Warfarin | 10/2864 (0.35) | 16/1666 (0.96) | 0.362 (0.164-0.799) | 0.245 (0.090-0.668) | ||
| Myocardial infarction | ||||||
| Overall | 14/5741 (0.24) | 16/3413 (0.47) | 0.519 (0.253-1.066) | 0.453 (0.212-0.972) | ||
| Apixaban | 6/2877 (0.21) | 6/1747 (0.34) | 0.606 (0.195-1.883) | .7213 | 0.549 (0.149-2.026) | .7003 |
| Warfarin | 8/2864 (0.28) | 10/1666 (0.60) | 0.464 (0.182-1.180) | 0.387 (0.152-0.985) | ||
| Death | ||||||
| Overall | 45/5741 (0.78) | 58/3413 (1.70) | 0.457 (0.309-0.676) | 0.396 (0.260-0.603) | ||
| Apixaban | 30/2877 (1.04) | 24/1747 (1.37) | 0.754 (0.440-1.295) | .0078 | 0.671 (0.372-1.210) | .0153 |
| Warfarin | 15/2864 (0.52) | 34/1666 (2.04) | 0.253 (0.137-0.466) | 0.201 (0.104-0.387) | ||
| Major bleeding | ||||||
| Overall | 81/5566 (1.46) | 79/3448 (2.29) | 0.624 (0.458-0.850) | 0.408 (0.288-0.578) | ||
| Apixaban | 46/2792 (1.65) [2] | 28/1768 (1.58) [6] | 1.023 (0.639-1.636) | .0041 | 0.787 (0.479-1.293) | .0086 |
| Warfarin | 35/2774 (1.26) [0] | 51/1680 (3.04) [11] | 0.406 (0.264-0.625) | 0.223 (0.133-0.374) | ||
| Major/CRNM bleeding | ||||||
| Overall | 133/5566 (2.39) | 154/3448 (4.47) | 0.517 (0.408-0.654) | 0.384 (0.297-0.497) | ||
| Apixaban | 72/2792 (2.58) [2] | 61/1768 (3.45) [6] | 0.736 (0.520-1.042) | .0058 | 0.633 (0.440-0.910) | .0118 |
| Warfarin | 61/2774 (2.20) [0] | 93 / 1680 (5.54) [12] | 0.373 (0.270-0.517) | 0.235 (0.162-0.342) |
*
[n] represents number of bleedings followed by death within 30 days.
†
Interaction between interruption and treatment
‡
Adjusted for age, CHADS2 score, bridging, major/nonmajor procedure, and emergency/nonemergency procedure.